Roche: Slow And Steady Wins The Race
This article was originally published in The Pink Sheet Daily
The firm got off to a solid start in 2016, which should see its biggest launches in years, but its core strength remains executing long-term management of its key franchises.
You may also be interested in...
Alectinib will launch within two weeks for second-line ALK-positive non-small lung cancer at the price of $12,500 per month.
Roche plans to file the selective CD20 antibody in 2016 after releasing positive Phase III data at ECTRIMS in both relapsing-remitting and primary progressive multiple sclerosis, a debilitating form of the disease for which there are no approved drugs.
The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.